Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review.

Graham WalterChrystyna KalicinskyRichard WarringtonMarianne MiguelJeannette ReyesTamar S Rubin

Published in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2020)

In a real-life setting, in the Manitoba adult PIDD population, SCIG push is an effective method of preventing severe infections, with most patients preferring to continue this therapy once initiated.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
low dose
stem cells
young adults
bone marrow
mesenchymal stem cells
patient reported